UPTAKE OF CLARITHROMYCIN BY RAT LUNG-CELLS

被引:33
作者
KOHNO, Y [1 ]
YOSHIDA, H [1 ]
SUWA, T [1 ]
SUGA, T [1 ]
机构
[1] TOKYO COLL PHARM,DEPT CLIN BIOCHEM,HACHIOJI,TOKYO 19203,JAPAN
关键词
D O I
10.1093/jac/26.4.503
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
To evaluate the affinity of clarithromycin (6-O-methylerythromycin A) for lung tissue, the in-vivo and in-vitro uptake of [14C]clarithromycin and ["14C]erythromycin by rat lung cells was compared, and the characteristics of the uptake mechanism were investigated. After the administration into the external jugular vein of rats, clarithromycin was found in much higher concentrations in the lung tissue than erythromycin. In isolated lung cells, clarithromycin was also found in greater concentrations than erythromycin. The amount of clarithromycin was ten times that of erythromycin after 5 min incubation. This uptake profile was quite different from that observed in isolated liver cells. Uptake by lung cells for both antibiotics was shown to be an active process, as revealed by the need for cell viability, a suitable environmental temperature and ATP. Clarithromycin uptake proved to be dependent in part upon mitochondrial oxidative respiration. Kinetic analysis indicated that clarithromycin transport was saturable, with a relatively high binding affinity and velocity of uptake. Clarithromycin transport was significantly inhibited by 6-O-methylerythromycin analogues, but was not influenced by other analogues, including erythromycin. Competitive inhibition of clarithromycin uptake was demonstrated by 6,11,12,4"-tetra-O-methylerythrornycin, one of the mutual inhibitors. These findings may suggest that clarithromycin utilizes a carrier-mediated transport system in the lung cells, which is common to 6-O-methylerythromycins. This difference of uptake mechanism between both antibiotics may account in part for the greater clarithromycin uptake by the lung cells. © 1990 by The British Society for Antimicrobial Chemotherapy.
引用
收藏
页码:503 / 513
页数:11
相关论文
共 22 条
  • [1] THE ISOLATION OF RAT LUNG-CELLS FOR THE PURPOSE OF STUDYING DRUG-METABOLISM
    DAWSON, JR
    NORBECK, K
    MOLDEUS, P
    [J]. BIOCHEMICAL PHARMACOLOGY, 1982, 31 (22) : 3549 - 3553
  • [2] DETTE GA, 1987, ARZNEIMITTEL-FORSCH, V37-1, P524
  • [3] KINETICS OF ERYTHROMYCIN UPTAKE AND RELEASE BY HUMAN-LYMPHOCYTES AND POLYMORPHONUCLEAR LEUKOCYTES
    DETTE, GA
    KNOTHE, H
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1986, 18 (01) : 73 - 82
  • [4] INVITRO AND INVIVO EVALUATION OF A-56268 (TE-031), A NEW MACROLIDE
    FERNANDES, PB
    BAILER, R
    SWANSON, R
    HANSON, CW
    MCDONALD, E
    RAMER, N
    HARDY, D
    SHIPKOWITZ, N
    BOWER, RR
    GADE, E
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1986, 30 (06) : 865 - 873
  • [5] HAND WL, 1983, J ANTIMICROB CHEMOTH, V12, P1
  • [6] MEMBRANE-TRANSPORT OF CLINDAMYCIN IN ALVEOLAR MACROPHAGES
    HAND, WL
    KINGTHOMPSON, NL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1982, 21 (02) : 241 - 247
  • [7] ENTRY OF ROXITHROMYCIN (RU-965), IMIPENEM, CEFOTAXIME, TRIMETHOPRIM, AND METRONIDAZOLE INTO HUMAN POLYMORPHONUCLEAR LEUKOCYTES
    HAND, WL
    KINGTHOMPSON, N
    HOLMAN, JW
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (10) : 1553 - 1557
  • [8] SPIRAMYCIN UPTAKE BY ALVEOLAR MACROPHAGES
    HARF, R
    PANTEIX, G
    DESNOTTES, JF
    DIALLO, N
    LECLERCQ, M
    [J]. JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1988, 22 : 135 - 140
  • [9] UPTAKE, INTRACELLULAR ACTIVITY, AND INFLUENCE OF RIFAMPIN ON NORMAL FUNCTION OF POLYMORPHONUCLEAR LEUKOCYTES
    HOGER, PH
    VOSBECK, K
    SEGER, R
    HITZIG, WH
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1985, 28 (05) : 667 - 674
  • [10] JOHNSON JD, 1980, J LAB CLIN MED, V95, P429